Compare Marqeta Inc (MQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs GeneDx Holdings Corp — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.66B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | WGS | |
|---|---|---|
Market Cap | $1.66B | $2.58B |
Sector | Technology | Technology |
52-Week High | $23.88 | $167.51 |
52-Week Low | $15.04 | $34.51 |
Enterprise Value | $970.76M | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive net cash flow of $86.42M in 2025. Recent developments include expansion of Google Wallet partnership and stablecoin card initiatives. Valuation metrics remain elevated with P/E of 180.89 and EV/EBITDA of 48.53 despite modest profitability margins.
MQ offers 26% upside to consensus price target of $19.00, supported by earnings estimate revisions and strategic partnerships. Key risks include high valuation multiples, competitive payment processing landscape, and the need to sustain recent profitability improvements. Institutional sentiment leans cautious with 59% hold ratings despite recent business momentum.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
